In a recent preclinical study of allergic rhinitis, the hPGDS inhibitor TAS-205 in combination with montelukast showed a significant additive inhibitory effect on eosinophil infiltration and nasal obstruction in the late phase, when compared to treatment with either active agent alone [73]. This evidence concerns the gene HPGDS and allergic rhinitis.